G protein-coupled receptor 183Genealiases: EBI2 · hEBI2
Q-omics provides the consensus-scored GPR183 profile across patient tissues and cancer cell-line models. GPR183 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, GPR183 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, GPR183 RNA expression shows 19,989 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where GPR183 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR183 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR183 survival associations across molecular data types. GPR183 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR183 RNA expression–survival associations across cancer types. High GPR183 expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, CESC, SKCM and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for GPR183 RNA expression.
This table summarizes GPR183 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GPR183. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR183 shows lower tumor expression in COAD, BLCA, LUSC and THCA and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher GPR183 RNA expression in tumor versus normal tissue (log2 FC = +1.848, t-test p < 0.001).
This table shows molecular features associated with GPR183 in patient tissues and cancer cell lines. In patient samples, GPR183 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR183 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
